drugset / Trial / NCT00407927

A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis

NCT00407927

Phase 2 Completed 571 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to determine the safety, efficacy and tolerability of two doses of the study drug compared to placebo for the treatment of subjects with seasonal allergic rhinitis.

Timeline

Start
2006-12
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinastine Small molecule 0.05 % Intranasal
Subject Epinastine Small molecule 0.1 % Intranasal